Glaukos Announces Commercial Availability of Epioxa for Incision-Free Keratoconus Care

Published on March 20, 2026
ALISO VIEJO, Calif.—Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medtech company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced the commercial availability of Epioxa HD/Epioxa, an advancement in corneal cross-linking for the treatment of keratoconus. Epioxa is now commercially available for ordering directly from Glaukos or through its specialty pharmaceutical distribution network, according to the announcement. Glaukos received U.S. Food and Drug Administration (FDA) approval for its Epioxa HD/Epioxa New Drug Application (NDA) for the treatment of keratoconus in October of last year.
Continue reading on website
Other news

Study Challenges Protective Role of Blue-blocking IOLs

March 20, 2026
It’s been theorized that the blue-light filtering effect of tinted IOLs may protect the retina from oxidative stress and other damage that contributes to the development of AMD and related conditions; however, growing evidence questions the validity of this assumption.  Photo: Rumex International. Click image to enlarge. Today’s cataract surgeons frequently opt to use yellow

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

March 20, 2026
BERKELEY HEIGHTS, N.J.—Kalaris Therapeutics, Inc. (Nasdaq: KLRS), a biopharmaceutical company focused on developing clinical-stage treatments for common retinal diseases, has released its financial results and provided business updates for the full year ended December 31, 2025. The company reported a net loss of $43.4 million for full-year 2025, a reduction from the net loss of $69.2 million recor